News & events

Upcoming events

See all upcoming events

Latest news

Fujirebio acquires Fluxus to accelerate new platform development based on ultra-high sensitivity detection technology

H.U. Group Holding Inc., and its wholly-owned subsidiary, Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Shinjuku-ku, Tokyo), today announced that Fujirebio Holdings has acquired all shares of Fluxus, Inc. (President & CEO: Peter Wagner; Location: California, USA; hereinafter "Fluxus"). The deal price of this acquisition has not been disclosed.

Read more

Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry

Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is expected to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary of Fujirebio Europe NV.

Read more

Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States

MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for the company’s Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic (IVD) test for the assessment of β-Amyloid pathology in patients being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline.

Read more

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.